For Immediate Release: November 26, 2019
Jill Hronek, Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103
E-mail: [email protected]
December’s SLAS Discovery Showcases Part Two of the Special Issue “Membrane Proteins: New Approaches to Probes, Technologies and Drug Design”
Newswise — Oak Brook, IL – The December issue of SLAS Discovery features part two of the two-part special issue, “Membrane Proteins: New Approaches to Probes, Technologies and Drug Design.”
In this issue, Guest Editor Veli-Pekka Jaakola, Ph.D., (Confo Therapeutics, Belgium) includes a series of articles focused on new screening tools and assays that find new chemical matter for medically relevant membrane protein targets. In addition, an overview of a new and emerging protein-lipid reconstitution methodology utilizing Styrene Maleic Acid (SMA) polymers is featured.
Other reviews and original research papers included in the special issue include:
- Visualization and Exploitation of Ex Situ Lipid-Protein Complexes in Native Nanodiscs
- Understanding Structure-Function Relationship of Equilibrative Nucleoside Transporter Family
- Screening of Chemical Libraries Using a Yeast Model of Retinal Disease
- Live In-cell Membranome cDNA Screen: A homogenous In-Cell Binding Assay to Study Membrane Protein-Ligand Interaction
- Development of a Cell-Based Assay Using Large-Scale Transient Transfections and High Content Imaging (HCI) to Detect Extracellular Binding Events
- Functional Expression of MRP4
- Stabilization of MRP4 Using Novel Solubilization Agents
Dr. Jaakola received his Ph.D. from the Institute of Biotechnology at the University of Helsinki (Finland). He joined the Oulu Biocenter at the University of Oulu (Finland) as a junior group leader in 2009, became an adjunct professor of biochemistry and molecular medicine in 2011 and transitioned to the Membrane Protein Lab Head at Novartis (Switzerland) in 2013. Jaakola is currently Head of Structural Biology at Confo Therapeutics (Belgium) where he continues to work in structural biology, structure-based drug discovery and development for GPCR targets.
Access to December’s SLAS Discovery issue is available at https://journals.sagepub.com/toc/jbxb/24/10 through December 20. For more information about SLAS and its journals, visit www.slas.org/journals.
SLAS (Society for Laboratory Automation and Screening) is an international community of 16,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing Life Sciences R&D, 2018 Impact Factor 2.192. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA).
SLAS Technology: Translating Life Sciences Innovation, 2018 Impact Factor 2.048. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).